Related Experiment Video
Updated: Aug 11, 2026
10:58
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
Current progress in the development of HIV vaccines
1Vanderbilt University, Pediatric Infectious Diseases, D-7235 MCN, Nashville, TN 37232-2581, USA. paul.spearman@vanderbilt.edu
Current Pharmaceutical Design
|March 7, 2006
Summary
Developing an effective preventive vaccine against human immunodeficiency virus (HIV) remains a critical global health challenge. Current research focuses on advanced vector technologies to elicit cellular immune responses, moving beyond earlier failed approaches.
Area of Science:
- Immunology
- Vaccinology
- Virology
Background:
- The human immunodeficiency virus (HIV) epidemic continues to expand globally.
- Developing a preventive HIV vaccine is the primary strategy for control.
- Past vaccine strategies using envelope glycoproteins have been unsuccessful.
Purpose of the Study:
- To review the current landscape of HIV vaccine development.
- To highlight vaccines in clinical trials and advanced preclinical stages.
- To discuss the role of immunopathogenesis and immune evasion in vaccine design.
Main Methods:
- Evaluation of modern vector technologies for cellular immune responses.
- Assessment of adenoviral and poxvirus vector systems.
- Review of novel live vector-based vaccine approaches.
Main Results:
- Recombinant monomeric envelope glycoprotein vaccines have been abandoned.
- Adenoviral vector systems show promise for HIV vaccine development.
- The efficacy of poxvirus-based regimens in humans requires further investigation.
Conclusions:
- The HIV vaccine field is dynamic and presents significant challenges.
- Advances in immunology and vaccine technology are crucial.
- Novel strategies are needed to generate effective neutralizing antibody responses against HIV.
More Related Videos
Related Concept Videos
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...